PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 21900690-6 2011 The JNK inhibitor SP600125 reduced ANG II-induced IRS-1 Ser307 phosphorylation (by 80%), IRS-1 Ser302 phosphorylation (by 70%), and IRS-1 Ser632 phosphorylation (by 50%). pyrazolanthrone 18-26 angiotensinogen Homo sapiens 35-41 31807542-9 2019 However, the proliferation and migration stimulated by Ang II were partly reversed by drug inhibitors of the four pathways, namely, PD98059, SB203580, SP600125 and XMD17-109. pyrazolanthrone 151-159 angiotensinogen Homo sapiens 55-61 29991018-11 2018 The enhancing effects of Ang II on EPC adhesion, migration and in vitro vasculogenesis were reversed by p38 inhibitor SB202190 and JNK inhibitor SP600125. pyrazolanthrone 145-153 angiotensinogen Homo sapiens 25-31 25591955-4 2015 METHODS AND RESULTS: We showed that Ang II significantly up-regulated the expression of Egr-1 in RAW264.7 macrophages, and this effect was markedly attenuated by Eprosartan (an AT1R blocker), SP600125 (a JNK-specific inhibitor) and PD98059 (an ERK-specific inhibitor). pyrazolanthrone 192-200 angiotensinogen Homo sapiens 36-42 20508392-7 2010 Olmesartan, U0126 (an ERK1/2 inhibitor), SP600125 (a JNK inhibitor), and PP2 potently inhibited AII-induced RASMC migration. pyrazolanthrone 41-49 angiotensinogen Homo sapiens 96-99 20490773-0 2010 SP600125, an inhibitor of c-Jun NH2-terminal kinase, blocks expression of angiotensin II-induced monocyte chemoattractant protein-1 in human mesangial cells. pyrazolanthrone 0-8 angiotensinogen Homo sapiens 74-88 20490773-9 2010 SP600125 also reduced MCP-1 mRNA stability: the halflife of MCP-1 mRNA was approximately 5 hours in cells treated with Ang II only, but was reduced to 2 hours when treated with a combination of Ang II and SP600125. pyrazolanthrone 0-8 angiotensinogen Homo sapiens 119-125 20490773-9 2010 SP600125 also reduced MCP-1 mRNA stability: the halflife of MCP-1 mRNA was approximately 5 hours in cells treated with Ang II only, but was reduced to 2 hours when treated with a combination of Ang II and SP600125. pyrazolanthrone 0-8 angiotensinogen Homo sapiens 194-200 20538278-11 2010 The further study indicated that losartan, NAC, PD98059, SP600125 significantly inhibited ERK1/2 and JNK phosphorylation, and PD98059, SP600125, PDTC completely antagonized AngII-induced CRP expression in HAECs. pyrazolanthrone 57-65 angiotensinogen Homo sapiens 173-178 20538278-11 2010 The further study indicated that losartan, NAC, PD98059, SP600125 significantly inhibited ERK1/2 and JNK phosphorylation, and PD98059, SP600125, PDTC completely antagonized AngII-induced CRP expression in HAECs. pyrazolanthrone 135-143 angiotensinogen Homo sapiens 173-178 19486902-8 2009 Anthra[1-9-cd]pyrazol-6(2H)-one (SP600125), an inhibitor of JNK, decreased the [(3)H]thymidine incorporation induced by angiotensin II. pyrazolanthrone 0-31 angiotensinogen Homo sapiens 120-134 19486902-8 2009 Anthra[1-9-cd]pyrazol-6(2H)-one (SP600125), an inhibitor of JNK, decreased the [(3)H]thymidine incorporation induced by angiotensin II. pyrazolanthrone 33-41 angiotensinogen Homo sapiens 120-134 15634454-9 2004 Significant down-regulation of AP-1 activation and MCP-1 expression were observed in angiotensin II-induced human mesangial cells pretreated with JNK specific inhibitor SP600125. pyrazolanthrone 169-177 angiotensinogen Homo sapiens 85-99 15701817-2 2005 Therefore, the present study was carried out to examine whether JNK is involved in ANG II-induced cell proliferation in cultured human mesangial cells (HMCs) with the use of a newly developed JNK-selective blocker, SP-600125. pyrazolanthrone 215-224 angiotensinogen Homo sapiens 83-89 15701817-5 2005 SP-600125 ranging from 5 to 10 microM almost completely abolished the activation of JNK by ANG II without affecting the activities of Erk1/2 and p38. pyrazolanthrone 0-9 angiotensinogen Homo sapiens 91-97 15701817-7 2005 Similarly, SP-600125 dose dependently reduced the ANG II-induced increase in cell number. pyrazolanthrone 11-20 angiotensinogen Homo sapiens 50-56 19338750-5 2009 Furthermore, Ang II-induced MMP 2 activation was markedly blocked by SP600125, a selective c-Jun N-terminal kinase (JNK) inhibitor, or pre-treatment of cells with antisense oligonucleotide to focal adhesion kinase (FAK), indicating that both molecules were important for the activation of MMP 2 by Ang II receptor stimulation. pyrazolanthrone 69-77 angiotensinogen Homo sapiens 13-19 33226363-9 2020 Conversely, these adverse events caused by AngII and MS were obviously reversed by ML3404 and SP600125. pyrazolanthrone 94-102 angiotensinogen Homo sapiens 43-48 31957305-10 2020 Hypoxia, hypoxia with HBO and exogenous addition of AngII also increased promoter transcription to visfatin; SP600125 and losartan blocked this activity. pyrazolanthrone 109-117 angiotensinogen Homo sapiens 52-57 31957305-7 2020 Visfatin protein expression increased in hypoxic HCAECs with earlier angiotensin II (AngII) secretion and c-Jun N-terminal kinase (JNK) phosphorylation, which could be effectively suppressed by the JNK inhibitor (SP600125), AngII antibody or AngII receptor blocker (losartan). pyrazolanthrone 213-221 angiotensinogen Homo sapiens 69-83 31957305-7 2020 Visfatin protein expression increased in hypoxic HCAECs with earlier angiotensin II (AngII) secretion and c-Jun N-terminal kinase (JNK) phosphorylation, which could be effectively suppressed by the JNK inhibitor (SP600125), AngII antibody or AngII receptor blocker (losartan). pyrazolanthrone 213-221 angiotensinogen Homo sapiens 224-229